Patents by Inventor Claus Bornaes
Claus Bornaes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8987202Abstract: Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to the human Factor VII or human Factor VIIa sequence shown in SEQ ID NO:1, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.Type: GrantFiled: June 14, 2006Date of Patent: March 24, 2015Assignee: Bayer Healthcare LLCInventors: Jesper Mortensen Haaning, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20120171765Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: ApplicationFiled: November 18, 2011Publication date: July 5, 2012Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 8084591Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: June 12, 2006Date of Patent: December 27, 2011Assignee: Bayer Healthcare LLCInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7807638Abstract: Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to human Factor VII or human Factor VIIa, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34 or having an amino acid substitution in position 36 of the amino acid sequence shown in SEQ ID NO:1; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.Type: GrantFiled: June 14, 2006Date of Patent: October 5, 2010Assignee: Bayer Healthcare LLCInventors: Jesper Mortensen Haaning, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7754682Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: October 30, 2007Date of Patent: July 13, 2010Assignee: Bayer Healthcare LLCInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7517974Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: March 30, 2006Date of Patent: April 14, 2009Assignee: Bayer Healthcare LLCInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7511024Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: April 12, 2006Date of Patent: March 31, 2009Assignee: Bayer HealthCare LLCInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20090030183Abstract: The invention relates to a conjugate exhibiting interferon ? (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: ApplicationFiled: September 8, 2008Publication date: January 29, 2009Inventors: Poul Baad Rasmussen, Joern Drustrup, Grethe Rasmussen, Anders Hjelholt Pedersen, Hans Thalsgard Schambye, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20090023635Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: ApplicationFiled: October 30, 2007Publication date: January 22, 2009Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7442524Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: June 12, 2006Date of Patent: October 28, 2008Assignee: Maxygen Holdings Ltd.Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7431921Abstract: The invention relates to a conjugate exhibiting interferon ? (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: GrantFiled: June 27, 2003Date of Patent: October 7, 2008Assignee: Maxygen ApSInventors: Poul Baad Rasmussen, Grethe Rasmussen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7427592Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: June 12, 2006Date of Patent: September 23, 2008Assignee: Maxygen Holdings Ltd.Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7414022Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: June 26, 2006Date of Patent: August 19, 2008Assignee: Maxygen Holdings Ltd.Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7371543Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: September 27, 2004Date of Patent: May 13, 2008Assignee: Maxygen Holdings Ltd.Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7338788Abstract: The present invention provides new interferon ? conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.Type: GrantFiled: January 24, 2003Date of Patent: March 4, 2008Assignee: Maxygen ApSInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes, Poul Baad Rasmussen
-
Publication number: 20070243588Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: ApplicationFiled: April 12, 2006Publication date: October 18, 2007Inventors: Anders Pedersen, Kim Andersen, Claus Bornaes
-
Patent number: 7238344Abstract: The present invention provides new interferon ? conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.Type: GrantFiled: December 19, 2002Date of Patent: July 3, 2007Assignee: Maxygen, Inc.Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes, Poul Baad Rasmussen
-
Publication number: 20070142280Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: ApplicationFiled: June 7, 2006Publication date: June 21, 2007Inventors: Anders Pedersen, Kim Andersen, Claus Bornaes
-
Publication number: 20070117756Abstract: Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to human Factor VII or human Factor VIIa, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.Type: ApplicationFiled: December 21, 2006Publication date: May 24, 2007Inventors: Jesper Haaning, Kim Andersen, Claus Bornaes
-
Patent number: 7144574Abstract: The invention relates to a conjugate exhibiting interferon ? (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: GrantFiled: February 26, 2002Date of Patent: December 5, 2006Assignee: Maxygen ApSInventors: Poul Baad Rasmussen, Grethe Rasmussen, Kim Vilbour Andersen, Claus Bornaes